Search the Newsreel

Accelerant Holdings Director Nancy Hasley Sells 20,489 Class A Shares Under 10b5-1 Plan

Nancy Hasley, a Director at Accelerant Holdings (NYSE: ARX), sold 20,489 Class A Common Shares on August 13, 2026, at a weighted average price of $19.5636 per share. This transaction was executed under a pre-established Rule 10b5-1 trading plan. Following the sale, Hasley's direct …

Celestica Inc (CLS) Shares Fall 3.6% -- GF Value Says Still Overvalued

Celestica Inc (CLS) shares dropped 3.6% to $335.05, and GuruFocus's GF Value indicates the stock is significantly overvalued by 134.8% compared to its intrinsic value of $142.67. Despite a strong GF Score of 85/100, driven by profitability and growth, its valuation rank is low. …

Celestica (NYSE:CLS) Shares Down 3.8% After Insider Selling

Celestica (NYSE:CLS) shares dropped 3.8% following the sale of 23,496 shares by CEO Robert Mionis, reducing his ownership by over 50%. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating with a target price of $438.86. The company recently reported strong quarterly …

Hain Celestial (HAIN) gains 9.97% holder led by CastleKnight group

Cellebrite DI (NASDAQ:CLBT) Posts Earnings Results, Beats Expectations By $0.06 EPS

Celestica (CLS) CEO Mionis sells 23,496 shares via trust under 10b5-1 plan

Celestica (CLS) CEO Robert Mionis indirectly sold 23,496 common shares on August 13, 2026, through "Mionis 2026 GRAT Number Two." The sales were executed under a Rule 10b5-1 plan adopted in March 2026, at weighted average prices ranging from $360.00 to $365.39 per share. …

Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Celcuity (NASDAQ:CELC) recently reported its quarterly earnings, missing analyst estimates with a loss of $1.44 per share against a consensus of $1.16, and revenue of $0.09 million, significantly below the $4.42 million forecast. Despite the financial miss, the company highlighted the FDA approval of …

Kaplan Fox is Investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Cellebrite DI Ltd. (NASDAQ: CLBT). This investigation follows Cellebrite's second-quarter results, which missed ARR projections, a reduction in full-year guidance, and an abrupt CEO change, leading to a significant 29% drop in …

Cellebrite DI Ltd (CLBT) Stock Up 3.1% and Still Undervalued -- GF Score: 84/100

Cellebrite DI Ltd (CLBT) shares rose 3.1% to $11.14 but are still considered undervalued with a GF Value estimate of $16.09, suggesting a 30.8% margin of safety. The stock boasts a strong GF Score of 84/100 due to robust fundamentals and growth potential, despite …

CLBT|Cellebrite DI Ltd|Price:11.110|Chg%:+0.310

Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …

Vericel (VCEL) director exercises 7,000 options and sells 7,000 shares

Vericel Corp director Kevin F. McLaughlin exercised 7,000 stock options at $13.05 per share and subsequently sold 7,000 common shares at $44.53 per share on August 12, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted in May 2025. The options …

HEXCEL CORP /DE/ SEC Filing (Aug 14, 2026)

This article reports on an SEC Form 144 filing by HEXCEL CORP /DE/ (HXL) on August 14, 2026. The filing indicates a proposed sale of securities by an individual who acquired common stock through a stock option exercise on the same date. The form …

ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ICCC) 2026-08-14

FuelCell Energy Inc. stock rises Friday, outperforms market

FuelCell Energy Inc. (FCEL) stock rose significantly on Friday, gaining 9.98% to $22.37, despite a generally negative day for the broader market. Both the NASDAQ Composite Index and the Dow Jones Industrial Average experienced declines. The company's stock closed 40.95% below its 52-week high …

Cellebrite DI (NASDAQ:CLBT) Given New $16.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for Cellebrite DI (NASDAQ:CLBT) from $20.00 to $16.00, while maintaining an "overweight" rating. This new target implies a potential upside of 45.79% from the stock's current price of $10.97. Other analysts have also adjusted their …

Suzano S.A. 2026 Q2 - Results - Earnings Call Presentation (NYSE:SUZ) 2026-08-13

This article presents the slide deck published by Suzano S.A. for its Q2 2026 earnings call, held on August 13, 2026. The content is provided by SA Transcripts, which specializes in earnings call documentation. It serves as a resource for investors interested in Suzano …

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a …

Goldman Sachs Group (HAIN) discloses 5.8% beneficial stake in Hain Celestial

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a 5.8% beneficial ownership stake in Hain Celestial Group, Inc. common stock, as reported in a Schedule 13G filing. This amounts to 5,225,157.27 shares, with shared voting and dispositive …

Legal & General Group (FCEL) reports 2.42M FuelCell Energy shares in 13G/A

Legal & General Group Plc and its investment management affiliates reported beneficial ownership of 2,419,645 shares of FuelCell Energy, Inc. common stock, representing 3.6% of the class. This disclosure was made in a SCHEDULE 13G/A filing, indicating shared voting and dispositive power among the …

Cellebrite DI (NASDAQ:CLBT) Sees Unusually-High Trading Volume After Strong Earnings

T. Rowe Price Associates (HXL) discloses 5.86M-share position in Hexcel

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, revealing a significant position in Hexcel Corp (HXL) common stock. The firm beneficially owns 5,863,390 shares, which accounts for 7.8% of Hexcel's common stock, with sole voting power over 5,845,753 shares and sole …

ImmuCell Q2 2026 slides: revenue gains offset by margin pressure

ImmuCell (NASDAQ:ICCC) reported mixed Q2 2026 results, with product sales up 11.5% to $7.2 million, but gross margin significantly compressed from 43.7% to 33.9%. Despite a tripling of net income to $1.8 million largely due to a $2 million legal settlement, the stock dropped …

ImmuCell Corporation - Common Stock ICCC

ImmuCell Corporation (ICCC) is a biotechnology company focused on veterinary products, particularly for enhancing immune health in livestock. The company's stock recently traded at $10.20, down 6.47%, and has a market cap of $78.93 million. Recent news highlights include Q2 2026 earnings results, increased …

Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

Earnings call transcript: Xcel Brands posts Q2 2026 EPS beat but revenue miss

Xcel Brands (XELB) reported a Q2 2026 non-GAAP loss of $0.21 per share, beating analyst expectations, but revenue of $1.1 million missed forecasts. The company is actively shifting its strategy towards influencer-led brands, with several new launches planned, aiming to leverage social media reach …

CLBT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Cellebrite DI Ltd.

SueWallSt has initiated an investigation into potential securities law violations by Cellebrite DI Ltd. (NASDAQ: CLBT) following a significant drop in its share price. The investigation stems from Cellebrite's Q2 2026 revenue falling below analyst expectations and the company subsequently lowering its full-year 2026 …

Cellebrite DI (CLBT) Cuts Guidance And Changes CEO, Is The Stock Now Cheap?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Cellebrite DI (CLBT) has come under fresh scrutiny after its August 13 Q2 2026 earnings report, guidance cut, and CEO transition, with Levi …

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G

T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 …

ImmuCell Q2 Earnings Call Highlights

Key Points Interested in ImmuCell Corporation? Here are five stocks we like better. Strong domestic growth drove results: Second-quarter product sales rose 11.5% year over year to $7.2 million, while net income increased to $1.8 million from $500,000. Domestic sales grew 27.7%, offsetting a …

Earnings call transcript: ImmuCell posts strong Q2 2026 sales growth, shares fall

Celcuity remains a Buy as FDA approval and strong trial data boost confidence in its cancer drug launch.

Celcuity Inc. has received a "Buy" rating following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its quick inclusion in NCCN Category 1 guidelines, which is expected to aid adoption. Despite high upfront commercial investments and a significant valuation, the company's strong cash …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

Is Celestica (CLS) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these …

Celestica Stock vs. Poet Stock : Which Is the Better Buy?

This article compares Celestica (TSX:CLS) and POET Technologies (TSXV:PTK) as artificial intelligence (AI) investment opportunities. Celestica, an established manufacturer, shows strong current performance with rising revenue and earnings, while POET, a photonics developer, presents a speculative long-term play with promising technology but unproven commercial …